Xxxxx, Ph. D., is a Policy Associate at HSRI. She conducts research and provides consultation services to help states develop individualized supports budgets. Prior to joining HSRI, Xxxx earned her doctorate in special education from the University of New Mexico with an emphasis on advocacy, social justice, and public policy. Xxxxx Xxxxxxx, X.X., M.S.W., is a Policy Analyst with HSRI. She works on projects that focus on strategic planning, home and community-based services, and systems redesign centered on establishing individualized supports budges for service recipients. Prior to joining HSRI, Alena worked at state protection and advocacy agencies Disability Rights Oregon and Equip for Equality, as a developmental disabilities support services personal agent in Oregon, and as an independent living specialist with a center for independent living in Iowa.
Xxxxx, Ph. D., P.Eng.
Xxxxx, Ph. The Corporation shall pay the Employee an annual base salary ("Base Salary") of two hundred forty thousand dollars ($240,000), payable in accordance with the usual payroll period of the Corporation. Base Salary will be adjusted periodically to reflect Employee's then current salary, which will be subject to an annual review in the sole discretion of the Board of Directors or its Compensation Committee, provided however, that the Base Salary may not be adjusted downward.
Xxxxx, Ph. The Employee has the full right, power and legal capacity to enter and deliver this Agreement and to perform his duties and other obligations hereunder. This Agreement constitutes the legal, valid and binding obligation of the Employee enforceable against him in accordance with its terms. No approvals or consents of any persons or entities are required for the Employee to execute and deliver this Agreement or perform his duties and other obligations hereunder.
Xxxxx, Ph. D. shall cease to serve as Chairman of the Board of Directors; provided, however, that it shall not be an Event of Default if (A) Dx. Xxxxx ceases to serve as Chairman of the Board of Directors due to (1) Dx. Xxxxx’x resignation as a director due to a material adverse change to the condition of Dx. Xxxxx or any member of Dx. Xxxxx’x immediate family or (2) a vote or written consent of stockholders of the Company, in which the requisite majority for approval of such removal by the stockholders of the Company does not include any stockholders who serve on the Board of Directors or who are Affiliates of any individuals who serve on the Board of Directors, (B) two designees of Genesis are appointed to serve on the Board of Directors within five (5) Trading Days following Dx. Xxxxx’x departure pursuant to Section 4.20 of the Purchase Agreement and (C) immediately following Dx. Xxxxx’x departure as Chairman of the Board of Directors and the appointment of the Genesis Designees, (i) a majority of the members of the Board of Directors of the Company qualify as independent directors under Section 5605(a)(2) of the rules of the Nasdaq Stock Market (the “Independence Rules”) and remain so qualified until the Debentures are either repaid or converted in full and (ii) the chairman of the Board of Directors of the Company qualifies as an independent director under the Independence Rules and remains so qualified until the Debentures are either repaid or converted in full;
Xxxxx, Ph. D., is a senior scientist; X. Xxxx Xxx, Ph.D., is a senior microbiologist; and Xxxxx
Xxxxx, Ph. D. Exhibit “B” Employment Agreement between Biovest International, Inc. and Xxxx Xxxxx, Ph.D.
Xxxxx, Ph. Associate Xxxx for Research The Xxxxx Xxxxxxx University School of Medicine 000 Xxxxxxx Xxxxxx Xxxxxxxxx, XX 00000 Xx. Xxxxx Xxxx Vice President Xxxxxxx and Woman’s Hospital 00 Xxxxxxx Xxxxxx Boston, Massachusetts 02115
Xxxxx, Ph. D. student at the Graduate Programme of Nuclear Engineering, Faculty for Mathematics and Physics, University of Ljubljana. Employed at JSI since 2007. Field of work: Fuel- coolant interactions.
Xxxxx, Ph. D. March 6, 2000 Page 2 Xxxxxx and/or Xxxxx, or their designees or successors (collectively, "Your Supervisor") will control and direct the manner in which you perform the services under this Agreement, including the details and means by which you provide your services. You will be an employee of Amgen for all purposes during the term of this Agreement and will not be an independent contractor. You will also be required to provide to Your Supervisor, upon their reasonable request, written or oral reports and/or copies of other written materials with regard to the foregoing. As we have discussed, the position of Special Advisor, Research is a part- time special assignment position in which you will be expected to work a minimum of ten (10) hours per month; however, you also agree that, to the extent that Your Supervisor requests, you will work up to twenty (20) hours per month. If requested by Your Supervisor, you agree to attend certain scientific meetings or programs related to your area of expertise so long as such meeting or program does not unreasonably interfere with your other activities. You will maintain a log showing the time you have spent performing the foregoing services and this log shall be deemed conclusive evidence of the time spent. Amgen, at any time, may request a copy of your log and you agree to provide such a copy within a reasonable period of time after the request is made. Furthermore, from time to time, your duties may require you to travel and attend meetings at various locations, including Amgen's Thousand Oaks facility, and you agree that no reasonable request by Your Supervisor for travel or attendance at meetings will be refused. Your Supervisor will work with you in scheduling any such business trips or meetings so that they do not unreasonably interfere with your other activities and Amgen will reimburse you for your reasonable travel expenses. We have agreed that your part-time special assignment will continue until July 31, 2002, subject to extension as you and Amgen may agree in writing or to earlier termination by you or Amgen as set forth in Paragraph 8 of this Agreement. As long as you are employed by Amgen, you will continue to be subject to Amgen's policies and procedures, including but not limited to those relating to the non-disclosure of proprietary and confidential information and you will continue to be subject to the Amgen Inc. Proprietary Information and Inventions Agreement, executed by you on or about July 2...
